secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001193125-23-276030
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Q3 net loss $3.2M, revenue $25.5M on $30M GSK milestone; FDA SPA for Phase 3 tebipenem HBr
--------------------------------------------------------------------------------

- Net loss $3.2M ($0.06/shr) vs $11.7M loss ($0.33/shr) YoY; revenue $25.5M vs $2.0M YoY driven by $23.2M GSK collaboration revenue.
- Cash $93.8M expected to fund operations into H2 2025; received $30M development milestone from GSK under tebipenem HBr license.
- FDA granted Special Protocol Assessment for Phase 3 PIVOT-PO trial of oral tebipenem HBr in cUTI/AP; enrollment start expected Q4 2023.
- Phase 2a SPR720 trial for NTM-PD ongoing; topline data expected H2 2024. IND for SPR206 planned Q4 2023.
- Sath Shukla appointed President and CEO (Aug 1); Esther Rajavelu named CFO and CBO (Nov 1), replacing prior CFO role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523276030/0001193125-23-276030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523276030/d572144d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-276030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer